Welcome to our research hub. We believe that the future of mental health treatment relies on recognizing that every nervous system is unique. By investigating the intersection of neurotype (such as Autism and ADHD), developmental trauma, and 5-MeO-DMT, our organization is building a missing bridge in psychedelic science: truly individualized, trauma-informed care.
A major crisis is unfolding in modern psychiatry: over 30% of individuals struggling with major depression do not respond to standard antidepressant medications. In clinical terms, this is known as Treatment-Resistant Depression (TRD). For decades, the medical community has struggled to understand why traditional daily pills leave millions of people behind.
Our research is exposing a profound, systematic explanation for this failure: the treatment-resistant population heavily overlaps with the massive global gap of undiagnosed neurodivergent adults.
When an undiagnosed, high-masking autistic or ADHD adult experiences severe nervous system burnout from a lifetime of masking, navigating sensory overload, and managing executive dysfunction, standard medical models misdiagnose it as generic, chemical depression.
Traditional interventions fail this hidden population for three core reasons:
Treating Burnout as a Chemical Shortage: You cannot cure a fundamentally exhausted, overstimulated nervous system by forcing more serotonin into it with a daily pill. Standard SSRIs often cause these individuals to feel completely numb, lethargic, or deeply detached.
The Mismatch of Neural Architecture: Autistic and ADHD brains process neurotransmitters (particularly dopamine and norepinephrine) and sensory data differently than neurotypical brains. Standard psychiatric medications assume a uniform brain structure, leading to high adverse reaction rates and low efficacy in atypical individuals.
Leaving the Somatic Loop Untouched: For neurodivergent individuals, chronic stress and developmental trauma are heavily expressed through physical, somatic responses (such as chest tightness, racing heart, and sensory meltdowns tracked in our research). Standard pharmaceuticals attempt to quiet the cognitive mind while leaving the over-activated autonomic nervous system entirely untouched.
If up to 90% of older autistic adults and 70% of adults with ADHD remain undiagnosed globally, they represent the true “hidden majority” cycling through failed psychiatric treatments.
By mapping specific neurotype traits—such as Neuro_Sensory overload, Neuro_Routine disruption, and Neuro_Literal communication preferences—our study isolates exactly why traditional care failed these individuals.
Fast-acting tryptamines like 5-MeO-DMT do not just nudge neurotransmitter levels; they act as a complete power cycle for an overloaded nervous system. When combined with our specialised, sensory-optimised, and direct preparation and integration frameworks, we are building a successful pathway for the exact population the standard psychiatric system gave up on.
Most clinical trials operate on a “one-size-fits-all” model, treating all brains as if they process data identically. However, individuals with atypical nervous systems often carry a higher baseline of daily sensory overload and process early childhood trauma through distinct somatic (body-based) loops.
By mapping how different neurotypes navigate the profound state of 5-MeO-DMT ego dissolution, our research moves away from generic protocols and moves toward highly targeted, safe, and effective treatment models.
Our ongoing research tracks participants across three major milestones (Baseline, 1-Month, and 6-Month) using clinically validated scales and custom neurotype markers.
Here is what the data from our cohort of approximately 200 participants shows:
The Data: 22% of our study participants identify as neurodivergent (including formally diagnosed and self-identified/suspected Autism, ADHD, or AuDHD).
The Impact: This closely mirrors or slightly exceeds the estimated global population average (15-20%), proving that neurodivergent individuals are actively seeking these modalities and desperately need tailored frameworks.
The Data: 74% of participants tracking high on baseline anxiety and depressive shutdown reported a significant, sustained reduction in physiological tension and intrusive worry at the 1-month follow-up.
The Impact: The data indicate that fast-acting tryptamines can effectively break chronic “fight-or-flight” loops, offering the nervous system a clean slate to begin long-term integration.
The Data: Participants scoring high on Neuro_Routine (high need for predictability) and Neuro_Sensory (severe sensory overwhelm) showed a 68% drop in somatic trauma triggers (like racing heart and chest tightness) by Month 6, provided they received specialised, explicit preparation.
The Impact: This is a monumental finding. It suggests that when the environment is meticulously controlled to accommodate sensory needs, the peak experience safely deconditions deeply held developmental trauma loops without dysregulating the participant.
We aren’t just collecting numbers; we are using this data to actively change how psychedelic care is administered globally. Your data directly fuels:
Customized Preparation Protocols: Participants with high Neuro_Literal scores require explicit, non-metaphorical coaching to feel safe before a session. Our data allows us to build manuals that teach facilitators exactly how to speak to literal minds.
Sensory-Optimized Environments: By tracking sensory overwhelm data, we are designing clinic and retreat spaces that minimize auditory and visual distress, preventing adverse “bad trips” caused purely by environmental overload.
Predictable Integration Timelines: Our 6-month data helps us map exactly when hyperfocused or routine-oriented minds hit their integration “walls” or “crashes,” allowing us to deploy targeted somatic aftercare right when they need it most.
This current dataset is just the foundation. As our organization expands its footprint in Europe and partners with academic institutions, our research roadmap includes several exciting new frontiers:
While our current study relies on self-reported psychological scales, our next phase will introduce wearable technology to track Heart Rate Variability (HRV) and brainwave activity via EEG before, during, and after sessions. This will give us hard, physiological proof of nervous system repair.
We plan to launch a sub-study focusing exclusively on participants who score exceptionally high in Neuro_Hyperfocus. We want to scientifically isolate whether a brain adapted to intense, singular focus handles the boundary-less state of Oneness differently, and if it leads to a higher rate of permanent, transformative insights.
We intend to extend our tracking from 6 months to 24 months to observe the true permanence of these interventions. Does a single, well-integrated 5-MeO-DMT session permanently alter a person’s baseline trauma score over a multi-year period? Our upcoming protocols aim to find out.
Whether you are a participant looking to contribute your anonymous data, an academic researcher looking to collaborate on European grants, or a practitioner training in our methodologies, your involvement shapes the future of mental health.